On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
As the global burden of diabetes continues to climb, so too does the impact of its most feared complications—including diabetic foot ulcers (DFUs), infections, and amputations. While tight glycemic control has long been a cornerstone of diabetic foot prevention, emerging therapies are now offering benefits that go beyond glucose reduction. In our newly accepted paper... Continue Reading →
A new study published in Diabetes Care sheds light on the comparative risks of peripheral artery disease (PAD)-related surgical events—such as amputations, stent placements, or vascular surgeries—between two classes of diabetes medications: sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP-4i). Conducted among U.S. veterans, this retrospective cohort study analyzed over 150,000 episodes of medication... Continue Reading →
A recent review in Medicina highlights the promising role of sodium-glucose cotransporter 2 inhibitors (SGLT2-i) in diabetic foot prevention, presenting a detailed analysis of their physiological impact and potential benefits. Diabetic foot ulcers and related complications remain significant challenges, contributing to high healthcare costs and morbidity. SGLT2-i, originally developed for blood glucose management in diabetes,... Continue Reading →
